Literature DB >> 10789987

Reversal of spontaneous progressive autoimmune encephalomyelitis by myelin basic protein-induced clonal deletion.

G X Zhang1, T T Liu, E S Ventura, Y Chen, A Rostami.   

Abstract

Autoimmune encephalomyelitis can be initiated spontaneously and developed progressively in TCR transgenic mice specific for myelin basic protein when exposed to non-sterile environment, thus more closely mimicking human multiple sclerosis. By intravenous administration of myelin basic protein, we succeeded in reversing the clinical and pathological signs of progressive spontaneous disease in these mice. Flow cytometry showed that the majority of transgenic T cells in lymph nodes and spleen as well as spinal cords of treated mice were deleted. Dramatically increased numbers of apoptotic cells were found in peripheral immune organs of treated animals. Proliferative responses of single transgenic T cell to autoantigen were significantly decreased in treated mice, indicating that the remaining T cells were anergic. Moreover, production of both Th1 and Th2 cytokines was suppressed. This study is the first demonstration of reversal of progressive, spontaneous autoimmune disease of the central nervous system, and provides direct evidence that apoptosis-induced clonal deletion, along with anergy of remaining cells, but not Th2 switch, play a major part in the reversal of this disease by intravenous administration of autoantigen.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10789987     DOI: 10.3109/08916939908994067

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  5 in total

1.  Soluble mannosylated myelin peptide inhibits the encephalitogenicity of autoreactive T cells during experimental autoimmune encephalomyelitis.

Authors:  Junda Kel; Judith Oldenampsen; Mariken Luca; Jan Wouter Drijfhout; Frits Koning; Lex Nagelkerken
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

2.  c-kit plays a critical role in induction of intravenous tolerance in experimental autoimmune encephalomyelitis.

Authors:  Farinaz Safavi; Hongmei Li; Patricia Gonnella; Elisabeth Rose Mari; Javad Rasouli; Guang Xian Zhang; Abdolmohamad Rostami
Journal:  Immunol Res       Date:  2015-03       Impact factor: 2.829

3.  Intravenous tolerance effectively overcomes enhanced pro-inflammatory responses and experimental autoimmune encephalomyelitis severity in the absence of IL-12 receptor signaling.

Authors:  Denise C Fitzgerald; Guang-Xian Zhang; Shuo Yu; Melissa L Cullimore; Zhao Zhao; Abdolmohamad Rostami
Journal:  J Neuroimmunol       Date:  2012-04-21       Impact factor: 3.478

4.  Selective depletion of CD11c+ CD11b+ dendritic cells partially abrogates tolerogenic effects of intravenous MOG in murine EAE.

Authors:  Limei Wang; Zichen Li; Bogoljub Ciric; Farinaz Safavi; Guang-Xian Zhang; Abdolmohamad Rostami
Journal:  Eur J Immunol       Date:  2016-10       Impact factor: 5.532

5.  Combination treatment with fingolimod and a pathogenic antigen prevents relapse of glucose-6-phosphate isomerase peptide-induced arthritis.

Authors:  Yuya Yoshida; Norihisa Mikami; Yuki Matsushima; Mai Miyawaki; Hiroki Endo; Rie Banno; Takumi Tsuji; Tetsuro Fujita; Takeyuki Kohno
Journal:  Immun Inflamm Dis       Date:  2016-06-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.